Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

CNTB.US Logo

CNTB.US - Current Price

$2.12

Company Information

▼
Company Name
Connect Biopharma Holdings Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US2075231017
CIK: 0001835268
CUSIP: 207523101
Currency: USD
Full Time Employees: 62
Phone: 858 727 1040
Website: https://www.connectbiopharm.com
Fiscal Year End: December
IPO Date: Mar 19, 2021
Description:

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

Address:

3580 CARMEL MOUNTAIN ROAD, San Diego, CA, United States, 92130

Directors & Officers

▼
Name Title Year Born
Dr. Barry D. Quart Pharm.D. CEO & Director 1957
Mr. David L. Szekeres J.D. President 1974
Ms. Lisa Peraza CPA Senior Vice President of Finance 1977
Mr. Jeff Cohn J.D. General Counsel & Corporate Secretary 1982
Mr. Sean T. Ristine Vice President of Human Resources 1970
Dr. Lei Sun Ph.D. VP of Biologics & Head of CMC 1964
Dr. Srikanth Pendyala M.D. Senior Vice President of Clinical Development(Consultant) NA
Ms. Kimberly J. Manhard Executive VP & Chief Development Officer 1960

Shares Statistics

▼
Shares Outstanding: 55.90M
Shares Float: 17.18M
% Insiders: 3,914.80%
% Institutions: 3,914.00%
Short % Float: 0.69%

Valuation Metrics

▼
Enterprise Value: $64.52M
Trailing P/E: 0.00
Forward P/E: 0.77

Financial Highlights

▼
Market Cap: $118.52M
EBITDA: $-54.69M
Book Value: $0.99
Earnings/Share: $-0.89
Profit Margin: 0.00%
Operating Margin: -110,481.25%
ROA (TTM): -38.67%
ROE (TTM): -66.80%
Revenue (TTM): $762.00K
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -98.70%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Sep 30, 2025 -0.31 -0.24 N/A -2,916.67%
Jun 30, 2025 -0.23 -0.22 N/A -454.55%
Mar 31, 2025 -0.19 -0.26 N/A 2,692.31%
Dec 31, 2024 -0.42 0.00 N/A N/A
Jun 30, 2023 -0.54 -6.92 N/A 9,219.65%

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $78.23M $N/A $101.28M $9.12M $92.17M
2023-12-31 $105.66M $N/A $125.89M $24.85M $101.04M
2022-12-31 $80.37M $N/A $177.01M $16.81M $-463.76M
2021-12-31 $268.02M $N/A $291.39M $18.82M $272.57M
2020-12-31 $154.73M $N/A $166.19M $323.20M $-157.01M
2019-12-31 $44.82M $N/A $54.05M $97.33M $-43.27M
2018-12-31 $61.34M $N/A $69.29M $88.70M $-19.41M

Watchlist

0

No stocks in watchlist